Home » SCOTUS Spin-Off: Novartis Seeks Preemption for Brand Drugmakers
SCOTUS Spin-Off: Novartis Seeks Preemption for Brand Drugmakers
The Novartis v. Fussman liability case pending before the Supreme Court should extend to prescription drugmakers similar preemptive protection from state court-ordered punitive damages as those now afforded generic drug companies, a brief filed by the Washington Legal Foundation argues.
Drug Industry Daily
Drug Industry Daily
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May